Elkon K B, Bonfa E, Weissbach H, Brot N
Hospital for Special Surgery, Cornell University Medical Center, New York, NY.
Adv Exp Med Biol. 1994;347:81-92. doi: 10.1007/978-1-4615-2427-4_9.
ARA occur in approximately 10% of randomly selected SLE patients but in up to 40% of patients with active disease. Anti-P antibodies appear to be a highly specific diagnostic marker for SLE since they are rarely detected in other multisystem autoimmune disorders. ARA are most frequently directed against the P proteins and the shared conserved C-terminus of the P proteins is immunodominant in almost all sera tested. Anti-P antibodies increase in titer in patients with active disease and have been reported to be detected more frequently in patients with severe behavioral disturbances. This may be particularly true of patients with affective disorders. The clinical utility of serological tests for anti-P in central nervous system lupus must await large, prospective studies. Other ARA antibodies have been detected in patients with SLE. These antibodies include anti-28S rRNA, anti-S10, and anti-L12. In all cases, the frequency with which these antibodies are detected is increased in sera containing anti-P. The P proteins and the 28S rRNA epitope play essential, but as yet undefined, roles in GTPase activity on the ribosome. The L12 protein is the mammalian homologue of the E. coli and yeast proteins known to bind to the 28S rRNA epitope. These findings indicate that some SLE patients produce autoantibodies against multiple components of a functionally related domain of the ribosome. This, in turn, supports the notion that the ribosome initiates and/or maintains autoantibody production. Despite the evidence supporting an antigen driven immune response, attempts to induce anti-P antibodies by immunization with autologous ribosomes in the autoimmune strain of mouse, MRL, have been unsuccessful. It therefore seems likely that the ribosomal components must be altered in some way to break tolerance or that other abnormalities of the immune system are necessary for autoantibody production. Immunization with foreign ribosomes induce anti-P autoantibodies in mice and in apparently normal humans infected with the hemoflaggelate, T. cruzi. The ability of the P proteins to break tolerance in these situations is, most likely, explained by the provision of a T cell epitope (the foreign P protein) together with the multivalency of the P proteins on the ribosome (which activate autoreactive B cells). We therefore propose (Fig. 5) a two-signal model for autoantibody production similar to that suggested for T-B collaboration in the normal immune response and also in the GVHD model of lupus.(ABSTRACT TRUNCATED AT 400 WORDS)
抗核糖体抗体(ARA)在随机选取的系统性红斑狼疮(SLE)患者中约10%出现,但在疾病活动期患者中高达40%。抗P抗体似乎是SLE的一种高度特异性诊断标志物,因为在其他多系统自身免疫性疾病中很少检测到。ARA最常针对P蛋白,且在几乎所有检测血清中,P蛋白共享的保守C末端具有免疫优势。抗P抗体在疾病活动期患者中的滴度升高,据报道在有严重行为障碍的患者中更频繁检测到。这在情感障碍患者中可能尤其如此。抗P血清学检测在中枢神经系统狼疮中的临床实用性必须等待大规模前瞻性研究。在SLE患者中还检测到其他ARA抗体。这些抗体包括抗28S核糖体RNA、抗S10和抗L12。在所有情况下,在含有抗P的血清中检测到这些抗体的频率增加。P蛋白和28S核糖体RNA表位在核糖体上的GTP酶活性中起重要但尚未明确的作用。L12蛋白是已知与28S核糖体RNA表位结合的大肠杆菌和酵母蛋白的哺乳动物同源物。这些发现表明,一些SLE患者产生针对核糖体功能相关结构域多个成分的自身抗体。这反过来支持了核糖体启动和/或维持自身抗体产生的观点。尽管有证据支持抗原驱动的免疫反应,但在自身免疫性小鼠品系MRL中用自体核糖体免疫诱导抗P抗体的尝试未成功。因此,似乎核糖体成分必须以某种方式改变以打破耐受性,或者免疫系统的其他异常对于自身抗体产生是必要的。用外来核糖体免疫可在小鼠以及感染锥虫的明显正常人类中诱导抗P自身抗体。在这些情况下,P蛋白打破耐受性的能力很可能是由于提供了一个T细胞表位(外来P蛋白)以及核糖体上P蛋白的多价性(激活自身反应性B细胞)。因此,我们提出(图5)一种自身抗体产生的双信号模型,类似于正常免疫反应以及狼疮移植物抗宿主病模型中提出的T - B协作模型。(摘要截断于400字)